7-乙酰氨基-4-羟基-2-萘磺酸钠盐 | 42360-29-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 7-乙酰氨基-4-羟基-2-萘磺酸钠盐
• 英文名称: Sodium 7-(acetylamino)-4-hydroxy-2-naphthalenesulfonate
• CAS: 42360-29-2
• 化学式: C12H11NNaO5S
• 分子量: 304.28
• InChiKey: XCFHECKZRSUUOH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.37
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• PHARMACEUTICAL COMPOSITIONS CONTAINING SULPHONIC ACID DERIVATIVES
  申请人：Italfarmaco, S.A.

  公开号：EP1602644A1

  公开（公告）日：2005-12-07

  A naphthalenesulfonic acid or quinolinesulfonic acid of formula (I), wherein A is N or a CR8 formula group, where R8 is H, OH, NR10R11, independently from one another, where R10 and R11 represent H or C1-C6 alkyl or a group of formula NH-CO-R12, where R12 is C1-C6 alkyl or C6-C10 aryl; R1 and R2 represent H or SO3R9, independently from one another, where R9 is H, ammonium or a cation of an alkali or alkaline-earth metal; R3 is H or OH; and R4, R5, R6 and R7 represent H, an NR10R11 or NH-CO-R12 group, independently from one another; on the condition that (i) at least one of R1 or R2 is SO3R9, and (ii) at least one of R4, R5, R6 or R7 is an NR10R11 or NH-CO-R12 group, or their pharmaceutically acceptable salts; and a pharmaceutically acceptable excipient.

  一种具有化学式（I）的萘磺酸或喹啉磺酸，其中A为N或CR8配方基团，其中R8为H、OH、NR10R11，独立地，其中R10和R11分别代表H或C1-C6烷基或配方NH-CO-R12的基团，其中R12为C1-C6烷基或C6-C10芳基；R1和R2独立地代表H或SO3R9，其中R9为H、铵或碱金属或碱土金属的阳离子；R3为H或OH；R4、R5、R6和R7独立地代表H、NR10R11或NH-CO-R12基团；条件是（i）R1或R2中至少有一个为SO3R9，（ii）R4、R5、R6或R7中至少有一个为NR10R11或NH-CO-R12基团，或它们的药用可接受盐；以及药用可接受的赋形剂。
• Pharmaceutical compositions containing sulphonic acid derivatives
  申请人：Banfi Tosi María Beatriz

  公开号：US20060160849A1

  公开（公告）日：2006-07-20

  A naphthalenesulfonic acid or quinolinesulfonic acid of formula (I), wherein A is N or a CR 8 formula group, where R 8 is H, OH, NR 10 R 11 , independently from one another, where R 10 and R 11 represent H or C 1 -C 6 alkyl or a group of formula NH—CO—R 12 , where R 12 is C 1 -C 6 alkyl or C 6 -C 10 aryl; R 1 and R 2 represent H or SO 3 R 9 , independently from one another, where R 9 is H, ammonium or a cation of an alkali or alkaline-earth metal; R 3 is H or OH; and R 4 , R 5 , R 6 and R 7 represent H, an NR 10 R 11 or NH—CO—R 12 group, independently from one another; on the condition that (i) at least one of R 1 or R 2 is SO 3 R 9 , and (ii) at least one of R 4 , R 5 , R 6 or R 7 is an NR 10 R 11 or NH—CO—R 12 group, or their pharmaceutically acceptable salts; and a pharmaceutically acceptable excipient.

  公式（I）中的萘磺酸或喹啉磺酸，其中A为N或CR8配方基团，其中R8为H，OH，NR10R11，独立地，其中R10和R11代表H或C1-C6烷基或配方为NH-CO-R12的基团，其中R12为C1-C6烷基或C6-C10芳基；R1和R2独立地代表H或SO3R9，其中R9为H，铵离子或碱金属或碱土金属阳离子；R3代表H或OH；R4、R5、R6和R7独立地代表H，NR10R11或NH-CO-R12基团；条件是（i）R1或R2至少有一个为SO3R9，且（ii）R4、R5、R6或R7至少有一个为NR10R11或NH-CO-R12基团，或其药学上可接受的盐；以及药学上可接受的赋形剂。